Inhibition of chemically induced skin carcinogenesis by sulindac is independent of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta)
- PMID: 16418176
- DOI: 10.1093/carcin/bgi346
Inhibition of chemically induced skin carcinogenesis by sulindac is independent of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta)
Abstract
Inhibition of cyclooxygenase-2 (COX2) by non-steroidal anti-inflammatory drugs (NSAID) is known to suppress skin carcinogenesis. It was further suggested that inhibition of COX2-derived prostaglandins by NSAIDs could reduce levels of putative endogenous ligands of peroxisome proliferator-activated receptor-beta (PPARbeta), and these ligands could potentiate tumorigenesis. However, it is currently unclear whether ligand activation of PPARbeta either inhibits or potentiates carcinogenesis. The present studies were designed to examine the mechanism of NSAID-mediated chemoprevention in skin, and, in particular, to determine the role of PPARbeta in this process. A two-stage skin carcinogenicity bioassay was performed using wild-type and PPARbeta-null mice that were fed either a control diet or one containing 0.32 g sulindac/kg diet. Significant inhibition of chemically induced skin carcinogenesis was observed in both wild-type and PPARbeta-null mice, and this was associated with a marked decrease in the concentration of skin prostaglandins including PGE(2) and PGI(2). Results from these studies demonstrate that inhibition of COX2 by dietary sulindac in mouse skin can effectively inhibit chemically induced skin carcinogenesis, and suggest that the mechanism underlying this chemopreventive effect is independent of PPARbeta. Additionally, results from these studies do not support the hypothesis that ligand activation of PPARbeta by COX-derived metabolites potentiates chemically induced skin carcinogenesis.
Similar articles
-
Chemoprevention of chemically induced skin tumorigenesis by ligand activation of peroxisome proliferator-activated receptor-beta/delta and inhibition of cyclooxygenase 2.Mol Cancer Ther. 2010 Dec;9(12):3267-77. doi: 10.1158/1535-7163.MCT-10-0820. Mol Cancer Ther. 2010. PMID: 21159610 Free PMC article.
-
Ligand activation of peroxisome proliferator-activated receptor-beta/delta and inhibition of cyclooxygenase-2 enhances inhibition of skin tumorigenesis.Toxicol Sci. 2010 Jan;113(1):27-36. doi: 10.1093/toxsci/kfp212. Epub 2009 Sep 11. Toxicol Sci. 2010. PMID: 19748995 Free PMC article.
-
Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPAR beta/delta) inhibits chemically induced skin tumorigenesis.Carcinogenesis. 2008 Dec;29(12):2406-14. doi: 10.1093/carcin/bgn219. Epub 2008 Sep 17. Carcinogenesis. 2008. PMID: 18799709 Free PMC article.
-
The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation.Cell Signal. 2006 Jan;18(1):9-20. doi: 10.1016/j.cellsig.2005.07.009. Epub 2005 Aug 16. Cell Signal. 2006. PMID: 16109478 Review.
-
Establishing the Role of PPARβ/δ in Carcinogenesis.Trends Endocrinol Metab. 2015 Nov;26(11):595-607. doi: 10.1016/j.tem.2015.09.004. Epub 2015 Oct 18. Trends Endocrinol Metab. 2015. PMID: 26490384 Free PMC article. Review.
Cited by
-
The chemopreventive efficacies of nonsteroidal anti-inflammatory drugs: the relationship of short-term biomarkers to long-term skin tumor outcome.Cancer Prev Res (Phila). 2013 Jul;6(7):675-85. doi: 10.1158/1940-6207.CAPR-13-0064. Epub 2013 May 16. Cancer Prev Res (Phila). 2013. PMID: 23682071 Free PMC article.
-
Quantitative high-throughput drug screening identifies novel classes of drugs with anticancer activity in thyroid cancer cells: opportunities for repurposing.J Clin Endocrinol Metab. 2012 Mar;97(3):E319-28. doi: 10.1210/jc.2011-2671. Epub 2011 Dec 14. J Clin Endocrinol Metab. 2012. PMID: 22170715 Free PMC article.
-
NO-Donating NSAIDs, PPARdelta, and Cancer: Does PPARdelta Contribute to Colon Carcinogenesis?PPAR Res. 2008;2008:919572. doi: 10.1155/2008/919572. PPAR Res. 2008. PMID: 18528523 Free PMC article.
-
Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: evaluation of potential chemopreventive activity.Cancer. 2012 Dec 1;118(23):5848-56. doi: 10.1002/cncr.27540. Epub 2012 May 17. Cancer. 2012. PMID: 22605570 Free PMC article. Clinical Trial.
-
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention.Nat Rev Cancer. 2012 Feb 9;12(3):181-95. doi: 10.1038/nrc3214. Nat Rev Cancer. 2012. PMID: 22318237 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials